Implantable access system for prolonged intrapleural immunotherapy

Driesen, Peter; Boutin, C; Viallat,; Astoul, P.; Vialette, J P; Pasquier, Jérôme

doi:10.1183/09031936.94.07101889

Cited by 23 publications

(7 citation statements)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IL-2 was infused continuously for 5 days at a mean dose of 21×10 6 IU·day -1 for 5 days [107]. Infusion was performed through an implantable port to avoid multiple punctures and infection [108].…”

Section: Intrapleural Treatment (Immunotherapy)mentioning

confidence: 99%

Malignant pleural mesothelioma

Boutin¹,

Schlesser²,

Frenay³

et al. 1998

Eur Respir J

Self Cite

170

View full text Add to dashboard Cite

The incidence of malignant pleural mesothelioma (MPM) has risen for some decades and is expected to peak between 2010 and 2020. Up to now, no single treatment has been proven to be effective and death usually occurs within about 12-17 months after diagnosis. Perhaps because of this poor prognosis, early screening has incited little interest. However, certain forms may have a better prognosis when diagnosed early and treated by multimodal therapy or intrapleural immunotherapy. Diagnosis depends foremost on histological analysis of samples obtained by thoracoscopy. This procedure allows the best staging of the pleural cavity with an attempt to detect visceral pleural involvement, which is one of the most important prognostic factors. Although radiotherapy seems necessary and is efficient in preventing the malignant seeding after diagnostic procedures in patients, there has been no randomized phase III study showing the superiority of any treatment compared with another. However, for the early-stage disease (stage I) a logical therapeutic approach seems to be neoadjuvant intrapleural treatment using cytokines. For more advanced disease (stages II and III) resectability should be discussed with the thoracic surgeons and a multimodal treatment combining surgery, radiotherapy and chemotherapy should be proposed for a randomized controlled study. Palliative treatment is indicated for stage IV. In any case, each patient should be enrolled in a clinical trial.

show abstract

Section: Intrapleural Treatment (Immunotherapy)mentioning

confidence: 99%

Malignant pleural mesothelioma

Boutin¹,

Schlesser²,

Frenay³

et al. 1998

Eur Respir J

Self Cite

170

View full text Add to dashboard Cite

show abstract

“…There are several attitudes to manage pleural and abdominal intracavitary refractory effusions in end stage patients [ 6 ]. The aim of the treatment is to improve quality of life by decreasing symptoms.…”

Section: Discussionmentioning

confidence: 99%

Management of malignant pleural effusion and ascites by a triple access multi perforated large diameter catheter port system

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Such systems had been initially used for intraperitoneal administration of chemotherapeutic agents to control peritoneal effusion caused by malignant tumors such as ovarian [5][6][7]. Driesen et al used an implantable access system for repeated intrapleural immunotherapy in patients with malignant mesothelioma [8].…”

Section: Introductionmentioning

confidence: 99%